-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage for the production of Trilagliptin succinate tablets, which were reported as imitations of Category 3, and sprinted for the first domestic imitation
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Trolagliptin succinate is a novel long-acting oral hypoglycemic drug developed by Takeda and Furiex, which is a dipeptidyl peptidase 4 (DPP-4) inhibitor
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
At present, Takeda's Trilagliptin succinate tablets have not yet been declared for listing in China
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
According to data from Minet.
com, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
com, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
DPP-4 inhibitor submitted by Kelun Pharmaceuticals for listing
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
For DPP-4 inhibitors, Kelun Pharmaceutical has submitted registration applications for 4 varieties, including tricagliptin succinate tablets, ticagliptin hydrobromide tablets, linagliptin tablets and sitagliptin phosphate tablets
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
For Trolagliptin succinate tablets, only Kelun Pharmaceuticals and CSPC have submitted marketing applications.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
It is worth mentioning that ticagliptin hydrobromide tablets are exclusively reported by Kelun Pharmaceuticals, and are expected to be approved as the first domestic imitation by the end of 2022
.
.
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage for the production of Trilagliptin succinate tablets, which were reported as imitations of Category 3, and sprinted for the first domestic imitation
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Trolagliptin succinate is a novel long-acting oral hypoglycemic drug developed by Takeda and Furiex, which is a dipeptidyl peptidase 4 (DPP-4) inhibitor
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
At present, Takeda's Trilagliptin succinate tablets have not yet been declared for listing in China
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
According to data from Minet.
com, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
com, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
DPP-4 inhibitor submitted by Kelun Pharmaceuticals for listing
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
For DPP-4 inhibitors, Kelun Pharmaceutical has submitted registration applications for 4 varieties, including tricagliptin succinate tablets, ticagliptin hydrobromide tablets, linagliptin tablets and sitagliptin phosphate tablets
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
For Trolagliptin succinate tablets, only Kelun Pharmaceuticals and CSPC have submitted marketing applications.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
It is worth mentioning that ticagliptin hydrobromide tablets are exclusively reported by Kelun Pharmaceuticals, and are expected to be approved as the first domestic imitation by the end of 2022
.
.
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage for the production of Trilagliptin succinate tablets, which were reported as imitations of Category 3, and sprinted for the first domestic imitation
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
.
Trolagliptin succinate is a novel ultra-long-acting oral hypoglycemic drug, which belongs to DPP-4 inhibitor
.
According to data from Minet.
com, in 2020, the sales of DPP-4 inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 3 billion yuan
.
Trolagliptin succinate is a novel long-acting oral hypoglycemic drug developed by Takeda and Furiex, which is a dipeptidyl peptidase 4 (DPP-4) inhibitor
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
.
The product was first approved for marketing in Japan in March 2015 and is the world's first once-weekly oral hypoglycemic drug
.
At present, Takeda's Trilagliptin succinate tablets have not yet been declared for listing in China
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
.
There are 6 DPP-4 inhibitors on the market in China, including sitagliptin phosphate tablets, saxagliptin tablets, alogliptin benzoate tablets, vildagliptin tablets, linagliptin tablets, hydrobromic acid Tigeliptin tablets
.
In addition to ticagliptin hydrobromide tablets, other five DPP-4 inhibitors have a number of generic drugs approved for marketing
.
According to data from Minet.
com, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacycom, in 2020, the market size of DPP-4 inhibitors in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacy terminals will exceed 3 billion yuan, a year-on-year increase.
up 29%
.
DPP-4 inhibitor submitted by Kelun Pharmaceuticals for listing
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
For DPP-4 inhibitors, Kelun Pharmaceutical has submitted registration applications for 4 varieties, including tricagliptin succinate tablets, ticagliptin hydrobromide tablets, linagliptin tablets and sitagliptin phosphate tablets
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
.
Among them, Linagliptin Tablets and Sitagliptin Phosphate Tablets have been approved for batch production and are deemed to have been reviewed
.
For Trolagliptin succinate tablets, only Kelun Pharmaceuticals and CSPC have submitted marketing applications.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
Kelun Pharmaceuticals has changed the registration status of this product to "under approval".
First imitation
.
It is worth mentioning that ticagliptin hydrobromide tablets are exclusively reported by Kelun Pharmaceuticals, and are expected to be approved as the first domestic imitation by the end of 2022
.
.
